TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04944264

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress Management and Resiliency Training (SMART) program
Description: The Stress Management and Resiliency Training (SMART) program (bensonhenryinstitute.org) is well validated comprehensive stress management program. It is designed to cultivate both the early recognition of stress in the mind and body, develop skills to mitigate stress and evoke the relaxation response and cultivate resiliency. It is an 8 session program, typically run in a live group setting. In this study's case it was delivered via a videoconferencing platform.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress Management and Resiliency Training (SMART) program
Description: The Stress Management and Resiliency Training (SMART) program (bensonhenryinstitute.org) is well validated comprehensive stress management program. It is designed to cultivate both the early recognition of stress in the mind and body, develop skills to mitigate stress and evoke the relaxation response and cultivate resiliency. It is an 8 session program, typically run in a live group setting. In this study's case it was delivered via a videoconferencing platform.
Study: NCT04556383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB004
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB004
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB004
Description: oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablet
Study: NCT05081297

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Qigong
Description: Qigong as a traditional chinese medicine technique, composed of several types of exercises: Baduanjin, taijiquan, yijinjing, baojiangong.
Study: NCT03808246

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: using the demo version of a self-injector pen
Description: Participants, whatever the arm they are included in, will have to use the demo version of the auto-injector pen during a simulation of an anaphylactic shock.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: using the demo version of a self-injector pen
Description: Participants, whatever the arm they are included in, will have to use the demo version of the auto-injector pen during a simulation of an anaphylactic shock.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: using the demo version of a self-injector pen
Description: Participants, whatever the arm they are included in, will have to use the demo version of the auto-injector pen during a simulation of an anaphylactic shock.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: using the demo version of a self-injector pen
Description: Participants, whatever the arm they are included in, will have to use the demo version of the auto-injector pen during a simulation of an anaphylactic shock.
Study: NCT01387542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone extended release (ER)
Description: Paliperidone ER 3 milligram (mg) or 6 mg or 9 mg or 12 mg oral tablets depending on investigator's discretion once daily for 10 weeks
Study: NCT02720042

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phasix™ Mesh
Description: A resorbable mesh prepared from poly-4-hydroxybutyrate (P4HB)
Study: NCT00959725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab (intravitreal, 2.0mg/0.05ml)
Description: One injection of intravitreal infliximab (2.0mg/0.05ml).
Study: NCT03484793

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AESOP service system
Description: Investigators develop an electronic reminder in CPOE system which notifies physicians when there appears to be an inappropriate prescription. At the time, a physician saves a typed prescription, our system analyzes the patient's medications, diseases and uses the knowledge base to determine whether a medication is uncommonly prescribed to all diseases in a given prescription. If the system detects the common associations of medications and diseases in a given prescription, it considers an appropriate prescription, and, if not, an actionable reminder is shown onscreen. To the right of each suggested uncommon medication is a reason why the reminder is appearing. Physicians can accept the reminder or ignore the reminder.
Study: NCT01994889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis
Description: Tafamidis 20 mg in soft gel capsules administered once a day for 30 months
Study: NCT02995148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987521
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z43-104)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPF Control
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
Study: NCT03197636

Intervention type: DRUG
Intervention: Pembrolizumab
Description: Pembrolizumab is already approved for treatment of malignant melanoma in advanced stages. We will investigate if sPD-1 or vitamin D status is changed in patients receiving pembrolizumab.
Study: NCT05499286

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Program
Description: Mindful Awareness and Resilience Skills for Adolescents (MARS-A) Curriculum
Study: NCT01994889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis
Description: Tafamidis 80 mg in soft gel capsules administered once a day for 30 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in soft gel capsules administered once a day for 30 months
Study: NCT03153722

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pediatric discharge process interventions
Description: As this is an iterative quality improvement process, interventions will be evidence-based and chosen to test effectiveness for addressing areas of discharge bottlenecks or inefficiency within our specific hospital's context. Examples of possible interventions may include implementation of a discharge risk assessment (as in Statile et al, Pediatrics 2016), institution of a medications-in-hand policy on hospital discharge (as in Sauers-Ford et al, Pediatrics 2016), or initiation of a ward discharge coordinator who will help coordinate outpatient follow-up for patients. Interventions will be implemented in a stepwise fashion, utilizing successive plan-do-study-act cycles, with a minimum 2 month period between interventions to monitor outcomes.
Study: NCT03060161

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health in the right measure
Description: Nutritional monitoring and individual guidance on regular physical exercise.
Study: NCT01898351

Intervention type: OTHER
Group type: OTHER
Intervention: Fava bean, Lupin, Beef meat, Green pea, Hemp, Buckwheat
Description: The intervention visit involves a test meal to be consumed by subjects attending the Human Nutrition Unit in the morning, following an overnight fast. The meal will be consumed within 15 minutes and blood (69 mL) and urine samples will be collected during 24 hours.~The test meals are designed to contain the same amount of proteins. Alternative protein meals: a number of bread buns for each meal containing individual alternative protein flours (green pea, lupin, hemp, buckwheat, fava beans). These will deliver 30 g of protein, the remainder being provided by white flour. The control (meat) meal: a lean beef steak containing 30 g of protein and a bun containing the same amount of white flour as used for the alternative protein bread buns.~The semi structured interview guide: will take place within the Human Nutrition Unit during one of the scheduled visits, once initial screening has taken place and participants have been selected. All interviews will be digitally recorded.
Study: NCT00335764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipifarnib
Description: given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: IV administration
Study: NCT01779258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glycerol, paraffin (liquid and white soft)
Description: 1 application in the morning and in the evening

Intervention type: DEVICE
Group type: OTHER
Intervention: Atopiclair®
Description: 1 application in the morning, in the afternoon and in the evening

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Locatop@
Description: During the Run-In period:~1 application in the morning and in the evening during a maximum of 21 days

Intervention type: DRUG
Group type: OTHER
Intervention: Locatop@
Description: During the Run-In period:~1 application in the morning and in the evening during a maximum of 21 days

Intervention type: DRUG
Group type: OTHER
Intervention: Locatop@
Description: During the Run-In period:~1 application in the morning and in the evening during a maximum of 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Locapred@
Description: During the 3 months study treatment:~1 application in the evening in case of flare

Intervention type: DRUG
Group type: OTHER
Intervention: Locapred@
Description: During the 3 months study treatment:~1 application in the evening in case of flare
Study: NCT00750334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine
Description: Drug given Daily x 14 days and 7 days of rest for 21 day cycle
Study: NCT01779258

Intervention type: DRUG
Group type: OTHER
Intervention: Locapred@
Description: During the 3 months study treatment:~1 application in the evening in case of flare
Study: NCT01792544

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Statement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Statement
Study: NCT00272025

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: 10mg to 20mg tablet daily for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01900210

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WaySafe
Study: NCT01012089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin
Description: Daptomycin IV 5 mg/kg one time dose
Study: NCT03423199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Tamoxifen, 20mg, orally once daily (continuously)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: Tamoxifen, 20mg, orally once daily (continuously)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: For pre/perimenopausal patients only: Goserelin, 3.6 mg, subcutaneously every 4 weeks; or 10.8 mg, subcutaneously every 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin
Description: For pre/perimenopausal patients only: Goserelin, 3.6 mg, subcutaneously every 4 weeks; or 10.8 mg, subcutaneously every 12 weeks
Study: NCT05094778

Intervention type: PROCEDURE
Group type: OTHER
Intervention: a single-portal palm approach
Description: a single-portal palm approach that passes superficially to palmar aponeurosis, and cut the full transverse carpal ligament.
Study: NCT02439489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120-CIS
Description: BKM120 will be delivered orally once daily on continuous at the dose of 60 mg (dose level 1), 80 mg (dose level 2) and 100 (dose level 3). Cisplatin will be delivered intravenously at the dose of 75 mg/m2 on day 1 every 3 weeks at each dose level of BKM120.~In the absence of BKM120 DLT, each level will be administered to 3 patients A minimum of 2 cycles per each dose level will be administered in the absence of disease progression or toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120-CARBO
Description: BKM120 will be delivered orally once daily on continuous at the dose of 60 mg (dose level 1), 80 mg (dose level 2) and 100 (dose level 3). Carboplatin will be delivered intravenously at AUC 5 on day 1 every 3 weeks at each dose level of BKM120. Should dose level 3 be completed, carboplatin will be given at AUC 6 and BKM120 at 100 mg.~In the absence of BKM120 DLT, each level will be administered to 3 patients A minimum of 2 cycles per each dose level will be administered in the absence of disease progression or toxicity
Study: NCT00625430

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gene Directed Enzyme Prodrug Therapy, FP253/Fludarabine
Description: Subjects within a treatment group will be administered a single transrectal intraprostatic injection of FP253.~Group A: 1 x 10Exp9 virus particles (VP); Group B: 3.2 x 10Exp9 VP; Group C: 1 x 10Exp10 VP; Group D: 3.2 x 10Exp10 VP; Group E: 1 x 10Exp11 VP; Group F: 3.2 x 10Exp 11 VP.~If there are no dose-limiting toxicities, three additional patients may be treated at the highest dose.~Twenty four hours following administration of the FP253, subjects will receive a first dose of fludarabine phosphate (20mg/m2 administered as an intravenous bolus). The first dose of fludarabine phosphate will be followed by 4 further doses at 24 hour intervals on treatment Days 3 to 6.
Study: NCT00750334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine
Description: Drug given Daily X 14 days and 7 days of rest for 21 day cycle
Study: NCT00864071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Griseofulvin 125 mg/5 mL Suspension, single dose
Description: A: Experimental Subjects received Alpharma formulated products under fasting conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Grifulvin V® 125 mg/5 mL Suspension, single dose
Description: B: Active comparator Subjects received Ortho Neutrogena formulated products under fasting conditions
Study: NCT02271178

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined capsule
Description: Combined capsule containing ramipril (5 to 10 mg), atenolol (50 to 100 mg), 100 mg aspirin, 40 mg simvastatin. In follow-up visits doses of atenolol and ramipril capsules may be adjusted according to blood pressure and heart rate.
Study: NCT01057589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Triplet Combination Therapy: 500 mg/m\^2 administered intravenously on Day 1 of 21 day cycle for up to 6 cycles~Maintenance Therapy: 500mg/m\^2 administered intravenously on Day 1 of 21 day cycle until disease progression or unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Triplet Combination Therapy: 400 mg/m\^2 administered intravenously on Day 1 of 21 day cycle for 1 cycle; 250 mg/m\^2 administered IV infusion on Day 1 of 21 day cycle and then weekly for up to 6 cycles.~Maintenance Therapy: 250 mg/m\^2 administered intravenously on Day 1 of 21 day cycle and then weekly until disease progression or unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Triplet Combination Therapy: 75mg/m\^2 administered intravenously on Day 1 of 21 day cycle for up to 6 cycles.
Study: NCT02271178

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional therapy
Description: Usual therapy
Study: NCT03871413

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRV-chair
Description: Repositioning maneuvers in TRV-chair
Study: NCT01057589

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: Standard of care dietary supplements: 350 to 1000 µg orally 5 times a day for the 7 days preceding the first dose of first dose of pemetrexed and continuing throughout treatment and for 21 days after the last dose of pemetrexed.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: Standard of care dietary supplements: 1000 µg IM during the week preceding the first dose of pemetrexed and every 9 weeks thereafter.
Study: NCT02712047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) (100 mcg)
Description: First blister strip contains FF blended with lactose, 100 mcg per blister

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilanterol (VI) (25 mcg)
Description: Second blister strip contains vilanterol blended with lactose and magnesium stearate, 25 mcg per blister

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will have two blister strips, identical in appearance to the inhaler containing active study medication; one containing lactose and the second strip containing lactose and magnesium stearate
Study: NCT03697915

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Experimental
Description: Conventional physical therapy was administered to the control group and was aimed at achieving sitting balance in the first phase; once sitting balance could be achieved, we aimed at achieving standing balance in the second phase. Once standing balance was also achieved, supported and unsupported ambulation was commenced in the final phase.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Conventional physical therapy was administered to the control group and was aimed at achieving sitting balance in the first phase; once sitting balance could be achieved, we aimed at achieving standing balance in the second phase. Once standing balance was also achieved, supported and unsupported ambulation was commenced in the final phase.
Study: NCT03871413

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual repositioning maneuver
Description: Treatment with manual repositioning maneuver
Study: NCT03197727

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: GC Saliva-Check BUFFER
Description: Evaluating the saliva flow rate, saliva pH and saliva buffering capacity
Study: NCT00128843

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: 25mg/day until progression disease

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1mg/day until progression disease
Study: NCT04587765

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extra-curricular sports
Description: The group follows the schedule of school teaching programme. Extra-curricular sports classes will be organized and provided in this group of schools in the afternoon after school until 6 p.m. (Monday to Friday).
Study: NCT03111186

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone Hcl 5Mg
Description: oxycodone HCl 5 mg up to six times daily as needed for pain

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 400 mg
Description: Ibuprofen 400 mg up to six times daily as needed for pain

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen 650 mg
Description: Acetaminophen 650 mg up to four times daily as needed for pain
Study: NCT03171181

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestibular reeducation
Description: Balance quality was registered with static and dynamic posturography. For spatial orientation is was registered Visual vertical and visual orientation perception. Vestibular disability was also assessed. Variables were registered at the beginning and at the end of a vestibular rehabilitation in UPVD participants. Vestibular rehabilitation consisted of 10 sessions of vestibular rehabilitation using dynamic posturography and visual reeducation. Duration of each session: 40 minutes. Twice a week.
Study: NCT05170932

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CHX gel 2 % + 24% EDTA
Description: The local drug delivery gel (24% of EDTA gel on root and bone surface and then application of 2% of chlorhexidine gel on root surface) were placed for group 2 in the periodontal pockets Filter paper were inserted into the orifice of the pocket for 1 minute. This was done in the day of surgery then after 3 days, 7 days, 14 days and 21 days after the local drug delivery to measure the gel release profile.
Study: NCT01516034

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cupola Tattoo Removal device
Description: Up to 6 treatments with the device every 2-3 weeks to the tattoo area.
Study: NCT03849625

Intervention type: DRUG
Intervention: aspirin, NSAIDs, paracetamol
Description: Perform skin test and/or provocation test with aspirin, paracetmol, or suspected NSAIDs in questionable cases
Study: NCT04340271

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy
Description: ESWT was conducted using the Duolith SD-1® device (StorzMedical, Tägerwilen, Switzerland) with an electromagnetic cylindrical coil source for the focused shock wave (Fig. 2). ESWT was performed around the primary treatment site at 100 impulses/cm2, an energy flux density(EFD) of 0.05 to 0.30 mJ/mm2, frequency of 4Hz, and 1000 to 2000 impulses were administered at 1-week intervals for 4 sessions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional occupational therapy
Description: Standard accupational therapy consist of range of motion exercise, strengthening exercises, and activities of daily living exercises

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: conventional occupational therapy
Description: Standard accupational therapy consist of range of motion exercise, strengthening exercises, and activities of daily living exercises
Study: NCT01818752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib was administered over 30 minutes on days 1, 2, 8, 9, 22, 23, 29, and 30 for nine 42-day cycles. Carfilzomib 20 mg/m² IV was administered on days 1 and 2 of cycle 1, followed by escalation to 36 mg/m² IV starting on day 8 of cycle 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Bortezomib 1.3 mg/m² was administered as a bolus IV injection or as a subcutaneous injection (per investigator's choice, dose modification, or regulatory approval) on days 1, 4, 8, 11, 22, 25, 29, and 32 of cycles 1 to 4, and on days 1, 8, 22, and 29 of cycles 5 to 9.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: Melphalan 9 mg/m² was taken orally on days 1 to 4 of all cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan 9 mg/m² was taken orally on days 1 to 4 of all cycles.
Study: NCT03600350

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pTVG-HP
Description: Plasmid DNA vaccine encoding Prostatic Acid Phosphatase (PAP)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a human programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of patients with multiple different types of cancer.